Patients with non-small cell lung cancer (NSCLC) show 30% EGFR mutations and 5% ALK translocations, which are driver mutation targeted by molecular target agents such as Gefitinib or ALK inhibitors. This evidence concerns the gene ALK and non-small cell lung carcinoma.